Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH

BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the trends spotted in 2024’s crop of more than 150 series A rounds — from top therapeutic areas and modalities to the leading investors funding the innovation. The editors turn to Washington for takeaways from BioCentury’s “exit interview” with P...